sar443765
mAbexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Jun 8, 2022 (NCT05366764)
Timeline
Indications
Mechanism of action
- Interleukin-13BINDING AGENT
IL13
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314848 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07190222 | Phase 3 | Sep 17, 2025 | Sanofi |
| NCT07190209 | Phase 3 | Sep 16, 2025 | Sanofi |
| NCT06914908 | Phase 2 | May 12, 2025 | Sanofi |
| NCT06790121 | Phase 2 | Feb 3, 2025 | Sanofi |
| NCT06676319 | Phase 2 | Nov 11, 2024 | Sanofi |
| NCT06609239 | Phase 2 | Sep 30, 2024 | Sanofi |
| NCT06454240 | Phase 2 | Jul 17, 2024 | Sanofi |
| NCT06102005 | Phase 2 | Oct 16, 2023 | Sanofi |
| NCT05366764 | Phase 1 | Jun 8, 2022 | Sanofi |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 9 | 9 | 3 | 2022 |
1 organizations
Page 1 / 1